Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA) gapped up before the market opened on Thursday . The stock had previously closed at $15.74, but opened at $16.59. Tyra Biosciences shares last traded at $16.18, with a volume of 15,912 shares.

Analyst Ratings Changes

TYRA has been the subject of a number of recent analyst reports. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Oppenheimer increased their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. HC Wainwright decreased their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and a consensus target price of $31.00.

Tyra Biosciences Trading Up 4.8 %

The company’s 50 day moving average is $21.51 and its 200 day moving average is $19.98. The stock has a market capitalization of $834.90 million, a price-to-earnings ratio of -9.78 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Analysts anticipate that Tyra Biosciences, Inc. will post -1.56 EPS for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the transaction, the director now directly owns 472,207 shares in the company, valued at approximately $7,635,587.19. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the sale, the chief executive officer now owns 1,355,927 shares of the company’s stock, valued at $37,830,363.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the sale, the director now directly owns 472,207 shares in the company, valued at approximately $7,635,587.19. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 101,050 shares of company stock worth $2,235,492. 15.40% of the stock is owned by company insiders.

Institutional Trading of Tyra Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Walleye Capital LLC boosted its holdings in Tyra Biosciences by 306.5% during the third quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock worth $2,976,000 after buying an additional 95,451 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Tyra Biosciences in the third quarter valued at about $593,000. Ally Bridge Group NY LLC lifted its holdings in shares of Tyra Biosciences by 2.0% in the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock valued at $6,349,000 after purchasing an additional 5,415 shares in the last quarter. FMR LLC lifted its holdings in shares of Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after purchasing an additional 26,187 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Tyra Biosciences in the third quarter valued at about $333,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.